Alzheimer’s disease: In the short run, no alternative to long clinical trials
As Alzheimer’s drugs keep failing clinically, the consensus among researchers in the field is that for the current approach – which is focused on amyloid beta – to work, treatments will have to start earlier.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter